J Clin Immunol (2017) 37:548–558 DOI 10.1007/s10875-017-0422-6 ORIGINAL ARTICLE Allogeneic Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease: a Single-Center Prospective Trial 1 2 2 2 2 Mark Parta & Corin Kelly & Nana Kwatemaa & Narda Theobald & Diane Hilligoss & 3 4 5 5,6 2 Jing Qin & Douglas B. Kuhns & Christa Zerbe & Steven M. Holland & Harry Malech & Elizabeth M. Kang Received: 20 February 2017 /Accepted: 13 July 2017 /Published online: 28 July 2017 US Government (outside the USA) 2017 Abstract dose total body irradiation for MUD recipients) with sirolimus Purpose The purpose of this study was to evaluate engraft- graft-versus-host disease prophylaxis. ment and adverse events with a conditioning and prophylactic Results Engraftment occured in 38/40 recipients (95%). Acute regimen intended to achieve high rates of engraftment with or chronic GVHD occurred in 18 (45%) and 5 (12.5%), respec- minimal graft-versus-host disease (GVHD) in allogeneic tively, with 6 episodes of grades III–IVand/or steroid refractory transplantation for chronic granulomatous disease in a single GVHD. Overall survival was 33/40 (82.5%) and event-free sur- center. vival was 30/40 (80%). Successful engraftment was associated Methods Forty patients, 37 male, with chronic granulomatous with myeloid and
Journal of Clinical Immunology – Springer Journals
Published: Jul 28, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera